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Introduction
Th e ﬁ rst human cell line was established in a Baltimore 
laboratory over 50 years ago by George Gey [1]. Th is cell 
line was HeLa – named after Henrietta Lacks, the lady 
from whom the cell line was derived, who had cervical 
carcinoma. Gey’s vision paved the way for cell culture as 
we know it today, allowing its widespread development 
into an important experimental tool in cancer research. 
One of the major beneﬁ ts of using cultured cell lines in 
cancer research is that they oﬀ er an inﬁ nite supply of a 
relatively homogeneous cell population that is capable of 
self-replication in standard cell culture medium.
Th e ﬁ rst breast cancer cell line to be established was 
BT-20 in 1958 [2]. It was another 20 years, however, 
before establishing breast cancer cell lines became more 
widespread, including the MD Anderson series [3] and 
what still remains the most commonly used breast cancer 
cell line in the world, MCF-7 established in 1973 at the 
Michigan Cancer Foundation [4]. Th e popularity of 
MCF-7 is largely due to its exquisite hormone sensitivity 
through expression of oestrogen receptor (ER), making it 
an ideal model to study hormone response [5].
Despite these early accomplishments, relatively few 
breast cancer cell lines have been established in the more 
recent past, mainly because of diﬃ  culties in culturing 
homo geneous populations without signiﬁ cant stromal 
contamination and, at least in the United Kingdom, 
partly due to rigorous ethical regulations surrounding 
obtaining human tissue for research [6]. Successes 
include the SUM series of 10 cell lines derived from 
either breast primary tumours, pleural eﬀ usions or 
various metastatic sites in individual patients [7]. Th ese 
cell lines are now widely available through commercial 
cell banks.
Breast cancer heterogeneity
Long before the advent of modern molecular proﬁ ling 
techniques, histopathologists recognised that breast cancer 
was heterogeneous through morphological observations. 
Classiﬁ cation was based on the following measures: 
histological type, tumour grade, lymph node status and 
the presence of predictive markers such as ER and, more 
recently, human epidermal growth factor receptor 2 
(HER2). Th e development of molecular proﬁ ling using 
DNA microarrays proved this heterogeneity, demon strat-
ing through gene expression proﬁ ling and the immuno-
histochemical expression of ERα, progesterone receptor 
(PR) and HER2 that breast cancer could be classiﬁ ed into 
at least ﬁ ve subtypes: luminal A, luminal B, HER2, basal 
and normal [8,9]. Molecular characteristics of these sub-
types are summar ised in Table 1.
Each subtype has diﬀ erent prognosis and treatment 
response [10]. Because ER is a therapeutic target, the 
luminal A and luminal B subtypes are amenable to 
hormone therapy. Similarly the HER2 group are potential 
candidates for trasuszumab therapy. In the current 
absence of expression of a recognised therapeutic target, 
basal tumours are diﬃ  cult to treat, more biologically 
aggressive and often have a poor prognosis. Because the 
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basal phenotype is characterised by the lack of expression 
of ERα, PR and HER2, it is sometimes referred to as 
triple-negative. Although there are similarities in the 
basal and triple-negative phenotypes, the terms are not 
strictly inter changeable; as outlined in a recent review, 
there is still no unifying deﬁ nition for basal cancers and, 
while triple-negative enriches for basal breast cancer, the 
phenotypes are not identical [11].
More recently the claudin-low subtype was described 
by interrogating established human and murine datasets 
[12]. Initially clustered with the basal subtype as a result 
of a lack of ERα, PR and HER2 expression and associated 
poor prognosis, these tumours were shown to be unique 
by the additional downregulation of claudin-3 and 
claudinin-4, low expression of the proliferation marker 
Ki67, enrichment for markers associated with the 
epithelial–mesenchymal transition and expression of 
features associated with mammary cancer stem cells 
(CSCs) (for example, CD44+CD24–/low phenotype) [13].
Do current breast cancer cell line models refl ect 
breast cancer heterogeneity?
Our group previously highlighted the pros and cons of 
using cell lines as in vitro models of breast cancer [14]. 
Although questions have been raised over how repre-
sentative immortalised cell lines are of human breast 
cancer [15], when used in the right way these remain 
powerful experimental tools and in many instances the 
information derived from these has translated into 
clinical beneﬁ t. A good example was the recognition that 
anti-oestrogens regulated the growth of tamoxifen-
stimulated MCF-7 cells [16,17], paving the way for the 
ultimate development and subsequent trials of fulvestrant 
(Faslodex®, AstraZeneca Pharmaceutical LP, Wilmington, 
DE, USA), a selective ER down regulator that is now 
recommended for the treatment of recurrent ER-positive 
metastatic breast cancer in the postmenopausal setting 
[18,19].
With the diﬀ erent molecular classiﬁ cations of breast 
cancer now ﬁ rmly established, researchers have turned 
their attention to breast cancer cell lines to determine 
whether the molecular proﬁ les observed in breast 
carcinomas are reﬂ ected in cell line models of the disease. 
A comprehensive evaluation of breast cancer cell lines by 
Lacroix and Leclercq, conducted before molecular 
proﬁ ling of breast cancer was widespread, concluded that 
while breast cancer cell lines have advanced our under-
standing of breast cancer biology, gaps still remained in 
terms of how representative these are [20] – in particular, 
the extent to which a single cell line can mirror the 
hetero geneity associated with clinical samples, the 
limited coverage of specialised histopathological types 
and whether the phenotype of a breast tumour in vivo is 
maintained in cell culture. Th is conclusion was reinforced 
in a breast cancer gap analysis [21]. Application of 
sophisticated transcriptional proﬁ ling to breast cancer 
cell lines using various platforms has gone some way to 
address these issues. In general, these studies have shown 
that the luminal, basal, HER2 and claudin-low clusters 
identiﬁ ed in breast tumours can easily be distinguished 
in breast cancer cell lines (Table 1) [13,22-26]. Of note is 
the ﬁ nding that the claudin-low subtype seems to be 
over-represented in breast cancer cell lines, possibly as a 
result of the ease of growth associated with cells that lack 
ERα, PR and HER2. Th ese cell lines provide good 
opportunities for the further study of this phenotype, 
which will enhance our understanding of its biology.
In an estimate of therapeutic response, luminal breast 
cancer cell lines preferentially responded to the AKT 
inhibitor GSK690693 and the phosphoinositide 3-kinase 
inhibitor GSK1069615, while proliferation of basal cell 
lines was selectively inhibited by the MEK protein kinase 
inhibitor GSK1120212 [27]. Th e response to trastuzumab, 
an antibody that selectively binds HER2, was evaluated in 
a panel of nine breast cancer cell lines with known HER2 
ampli ﬁ cation, but only three out of nine cell lines showed 
an unequivocal response [22]. Th is is in line with clinical 
observations reporting an eﬃ  cacy of 34% for trastuzumab 
[28] and serves to highlight that relying on a single cell 
line could generate incorrect or misleading data. Th ese 
Table 1. Molecular classifi cation of breast carcinoma
   Example cell lines
Classifi cation Immunoprofi le Other characteristics (adapted from [13,22])
Luminal A ER+, PR+/–, HER2– Ki67 low, endocrine responsive, often chemotherapy responsive MCF-7, T47D, SUM185
Luminal B ER+, PR+/–, HER2+ Ki67 high, usually endocrine responsive, variable to chemotherapy. HER2+ are  BT474, ZR-75
  trastusumab responsive
Basal ER–, PR–, HER2– EGFR+ and/or cytokeratin 5/6+, Ki67 high, endocrine nonresponsive, often  MDA-MB-468, SUM190
  chemotherapy responsive 
Claudin-low ER–, PR–, HER2– Ki67, E-cadherin, claudin-3, claudinin-4 and claudinin-7 low. Intermediate response  BT549, MDA-MB-231, 
  to chemotherapy Hs578T, SUM1315
HER2 ER–, PR–, HER2+ Ki67 high, trastusumab responsive, chemotherapy responsive SKBR3, MDA-MB-453
EGFR, epidermal growth factor receptor; ER, oestrogen receptor; HER2, human epidermal growth factor receptor 2; PR, progesterone receptor.
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studies indicate the need for a more rational approach for 
screening potential new breast cancer therapies by taking 
into account the diﬀ erent subgroups and recognising that 
response may not always be identical even within 
subgroups.
Breast cancer cell lines as models of mammary 
cancer stem cells
Stem cells are characterised by their ability to yield new 
tumours when xenografted into immunodeﬁ cient mice. 
Th is was ﬁ rst demonstrated in breast cancer by Al-Hajj 
and colleagues, who showed that as few as 100 to 200 
breast CSCs with the phenotype CD44+CD24−/lowLin− 
were capable of forming tumours when introduced into 
the mammary fat pad of NOD/SCID mice [29]. Now-
adays, breast CSCs are identiﬁ ed by one or more of the 
following features: their ability to form tumours in vivo; 
mammosphere formation in vitro; expression of aldehyde 
dehydrogenase; or through expression of cell surface 
biomarkers, usually the CD44+/CD24–/low phenotype [30].
Increasingly demonstrated is that very small numbers 
of CSCs (often described as tumour-initiating cells) exist 
within human breast cancer cell lines [31,32]. Th ere are 
clearly many advantages to working with CSCs derived 
from cell lines as they may be good models to further 
understand stem cell biology and develop CSC-speciﬁ c 
therapeutic targets. Two major obstacles need to be 
overcome, however, before these can be developed for 
routine use: CSCs are very much in the minority within a 
given tumour population, and CSCs have extremely slow 
population-doubling times. Improved enrichment methods 
are required to provide suﬃ  cient numbers of CSCs to 
conduct these types of studies, and their slow prolifera-
tion rates are challenging when it comes to experi-
mentally testing potential new therapeutics.
The cell culture environment
Complex inter-relationships that exist between cells in 
vivo are lost when cell lines are cultured on plastic in two 
dimensions, yet two-dimensional culture still remains the 
most favoured mechanism for in vitro studies in breast 
cancer research. In addition, cell lines are often sensitive 
to culture conditions – particularly the inclusion of 
growth factors that can sometimes alter the cell pheno-
type, resulting in inappropriate pathway activation or 
diﬀ erentiation. For example, when epidermal growth 
factor – a common component in media designed to culture 
breast myoepithelial cells – is included in luminal epi-
thelial cell culture, this can induce loss of expression of 
E-cadherin characteristic of epithelial to mesenchymal 
transition and the cells exhibit a more motile phenotype 
[33] Culture under inappropriate conditions can also 
drama ti cally inﬂ uence cell morphology, cell–cell and 
cell–matrix interactions, cell polarity and diﬀ erentiation 
[34,35], as well as altering signalling cascades and gene 
expression [36]. Identiﬁ cation of the most appropriate 
conditions to maintain the desired cell phenotype is thus a 
critical issue. As well as considering the molecular proﬁ les 
of breast cancer cell lines, we also need to look beyond 
simple two-dimensional breast cancer models. Th ere has 
thus been a shift in growing cells in more physiologically 
relevant three-dimensional systems with the increased 
complexity of including multiple cell types [34,37].
As highlighted by Kenny and colleagues, cell morphology 
in three dimensions is diﬀ erent from that observed in 
two dimensions on tissue culture plastic [38]. In two 
dimensions, luminal-like epithelial cells demonstrated 
the classic cobblestone morphology and expression of 
cell–cell adhesion molecules such as E-cadherin, whereas 
basal epithelial cells displayed a more elongated and spiky 
appearance and expressed markers of epithelial–mesen-
chymal transition such as vimentin. In contrast, cell lines 
grown in three-dimensional culture showed four diﬀ erent 
morphologies: round, mass, grape-like and stellate [38]. 
MCF12A normal mammary epithelial cells formed round 
polarised acini-like structures similar to those seen in 
normal human breast tissue. Luminal A T47D and 
MCF-7 cells and luminal B BT474 cells formed tightly 
cohesive structures displaying robust cell–cell adhesions. 
In contrast, basal MDA-MB-468, claudin-low MDA-
MB-231, and HER2-positive MDA-MB-453 and SKBR3 
all formed loosely cohesive grape-like or stellate 
structures consistent with the more invasive phenotype 
they demonstrate in vitro [22]. Examples of the type of 
cell morphology we routinely observe when luminal A 
and HER2-positive cells are grown in two-dimensional 
and three-dimensional cultures are shown in Figure 1 
and present close parallels with the study by Kenny and 
colleagues [38].
Functional three-dimensional studies have led to a 
greater understanding of normal breast structure and 
development; for example, by deﬁ ning a role for laminin 
V and desmogleins in epithelial cell polarity and main-
tenance of normal tissue architecture [35,39,40]. Th ree-
dimensional models have also provided an insight into 
the biology of breast cancer by implicating a role for β1-
integrin in breast cancer progression and by use of 
blocking antibodies to reverse the malignant phenotype 
of epithelial cells [41]. With the role of the stroma in 
regulating breast cancer behaviour receiving increased 
attention [42-44] and the recent recognition that basal 
and luminal breast cancers behave very diﬀ erently when 
co-cultured with stromal ﬁ broblasts [45], other three-
dimensional breast cancer models have incorporated 
stromal cells such as ﬁ broblasts [46], macrophages [47] 
and endothelial cells [48].
Increasing the complexity of these models is not 
without its problems, identiﬁ cation of individual cell 
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populations within multicellular structures is particularly 
challenging and diﬃ  culties in quantifying structures 
formed remain an issue, although computer-based 
methods of morphological analysis show potential [49]. A 
recent study has successfully modelled preinvasive ductal 
carcinoma in situ by co-culturing tumour cells with 
myoepithelial cells, observing ductal carcinoma in situ 
structures similar to those seen in clinical specimens 
[46]. Further addition of tumour-associated ﬁ broblasts 
resulted in tumour cell invasion and morphology remini-
scent of invasive carcinoma [46]. Although this is a big 
advance towards modelling the stages of breast cancer 
progression, the gold standard that is yet to be achieved 
is to enable co-evolution of tumour and stromal compo-
nents in vitro.
Th ese complex multicellular three-dimensional cultures 
are not just a tool for understanding disease progression, 
but may have important implications in drug screening. 
Th is was highlighted recently by Pickl and Ries [50], who 
demonstrated a signiﬁ cantly higher response of SKBR3 
cells to trastuzumab when the cells were cultured in three 
dimensions compared with cells cultured in two 
dimensions. Th ree-dimensional models may thus become 
a more widespread tool for research and drug screening, 
and while these models are technically challenging to 
establish, they are in the long term much more 
biologically relevant models for studying the disease in 
vitro.
While existing three-dimensional breast cancer models 
are moving towards the addition of some of the cellular 
components found within the complex breast tumour 
micro environ ment [46,51], inclusion of CSCs has thus far 
been overlooked. Addition of stem cells derived from the 
various cell types within the breast tumour micro environ-
ment may augment these in vitro three-dimen sional 
studies. With the diﬃ  culties in enriching for CSCs and 
their slow proliferation rates, this is not a trivial task. 
Nevertheless, more complex heterotypic models are 
required to fully model the in vivo cellular environment – 
a systems biology approach is needed to tackle this.
Th e choice of cell culture medium becomes increasingly 
relevant, with complex cultures containing multiple cell 
types where media for one cell type may inﬂ uence the 
phenotype of the co-cultured cell population. Th is in 
itself may present problems; having to rely on a single 
type of media to support cell types that may have quite 
diﬀ erent media requirements is challenging and empha-
sises the need for correct controls and robust standardi-
sation of methodology.
Cell lines in xenograft studies
Whilst xenograft models provide a whole organism 
environment for tumour growth, these too have limita-
tions. Experiments are usually performed in immuno-
com promised mice, which can impact on tumour 
formation and progression. Th e site of implantation is an 
important consideration, with injections into the mammary 
fat pad considered more physiologically relevant than 
subcutaneous injections even though the mouse and 
human mammary glands have quite diﬀ erent structures. 
Another confounding variable is the distinct diﬀ erence 
between the stroma of human and mouse mammary 
tissue, which casts doubt on the relevance of xenograft 
models [52]. As discussed above, the stroma is now 
recognised to inﬂ uence breast tumour cells. Th e diﬀ ering 
biology of mouse and human stroma together with 
reports of spontaneous transformation of mouse stroma 
by human breast tumour xenografts, resulting in hybrid 
mouse–human nuclei within the xenograft [53], raise 
further concerns. Several groups have tried to overcome 
this by co-injecting human ﬁ broblasts with cancer cell 
lines [54,55], but this does not allow for co-evolution of 
tumour and stroma that would happen during cancer 
development.
Of the cell lines commonly incorporated into xenograft 
models, ER-positive luminal A cell lines such as MCF-7 
and T47D will only form tumours in the presence of 
oestrogen and, unsurprisingly, growth can be inhibited 
by anti-oestrogen therapy. Cell lines representing other 
subtypes (for example, BT474, MDA-MB-468 and MDA-
MB-231) have also been shown to be tumourigenic; 
however, cells representing the HER2 subtype, including 
Figure 1. Cell morphology of cell lines grown in two-
dimensional and three-dimensional cultures. Two-dimensional 
culture of (a) luminal A T47D and (b) HER2-positive MDA-MB-453 cell 
lines grown on tissue culture plastic. T47D cells demonstrate a tightly 
cohesive cobblestone appearance, whereas MDA-MB-453 cells have 
an elongated and spindly appearance. (c) T47D and (d) MDA-MB-453 
cell lines cultured in three dimensions as previously described [46]. 
T47D cells form tightly cohesive mass structures displaying robust 
cell–cell adhesions, whereas MDA-MB-453 cells form loosely cohesive 
grape-like structures consistent with morphology observed by Kenny 
and colleagues [38].
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SKBR3 and MDA-MB-453 cells, have poor tumourigenic 
potential.
An unexpected ﬁ nding with xenograft models is the 
limited ability of tumours to invade and metastasise, 
particularly given the often metastatic origin of cell lines 
(reviewed in [14]). If metastasis occurs it is usually to the 
lung, which is not the most common metastatic site in 
human breast cancer – thus breast cancer metastasis is 
often studied through intravenous injection, enabling 
colonisation of speciﬁ c organs; for example, intracarotid 
artery injection for study of brain metastasis or left 
ventricle injection for metastasis to bone. Cell lines such 
as MDA-MB-231 that are regarded as invasive in vitro 
remain relatively poorly metastatic in vivo, although 
when introduced directly into the circulation the cell line 
has proved useful in models of experimental metastasis. 
Th rough rounds of in vivo selection, elegant experiments 
by Massague’s group have developed highly metastatic 
derivatives of MDA-MB-231 cells that home to particular 
metastatic sites, enabling generation of gene expression 
signatures linked with a speciﬁ c metastatic site [56]. 
Using the human breast cancer cell line SUM1315 
derived from a clinical sample of a metastatic node, 
Kupperwasser and colleagues introduced this as an 
ortho topic model into immunodeﬁ cient (NOD/SCID) 
mice bearing grafts of human bone, and showed the cells 
preferentially and spontaneously metastasised to the 
human bone graft rather than mouse skeleton [57].
MDA-MB-435 cells
A review of this nature would be incomplete without 
refer ence to MDA-MB-435 cells, which are sponta neously 
metastatic. A catalogue of the genomic and molecular 
properties of a breast cell line panel classiﬁ ed MDA-
MB-435 cells as basal B [22]. Hollestelle and colleagues 
also characterised MDA-MB-435 as a basal cell line 
through gene expression microarray proﬁ ling [26]. Th e 
provenance of this cell line, however, is hotly debated. 
Originally isolated as part of the MD Anderson series 
(hence the MDA preﬁ x [58]), these cells were thought to 
be derived from a breast carcinoma, but subsequent 
microarray and immunohistochemistry data have indi-
cated that MDA-MB-435 might originate from mela-
noma [59-61].
Despite clear controversies surrounding MDA-
MB-435, many researchers continue to use this as a bona 
ﬁ de breast cancer cell line. We believe the persistent use 
of this cell line, including publications in high-impact 
journals – for example, where MDA-MB-435 was used as 
a model of triple-negative breast cancer [62] – and even 
in specialist breast cancer journals [63,64], is unaccep-
table as it is likely to generate potentially misleading data. 
Nevertheless researchers are now more aware of the 
provenance of MDA-MB-435 cells, with two recent 
papers using the cell line as a melanoma model [65,66] 
and its inclusion in a 2010 list of cell lines of questionable 
origin [67]. We urge researchers, members of grant 
review panels and journal reviewers and editors to be 
more aware of this. Indeed, many journals now have a 
policy of requesting some form of cell line authentication 
to accompany manuscript submission, which is some-
thing we support.
Breast cancer cell lines that still need to be 
developed
Although there are now a reasonable number of breast 
cancer cell lines available to reﬂ ect the molecular sub-
groups, relevant models are lacking for some of the rarer 
histopathological types. Th ere is a single report on the 
development of two cell lines from phyllodes tumours 
[68] but these do not seem have gained widespread use. 
Cell lines derived from inﬂ ammatory breast cancer are 
limited to SUM149 and SUM190 [7], but the prevalence 
of the basal phenotype in this group [69] suggests basal 
cell lines may be used as surrogates. To our knowledge 
there is no known cell line derived from male breast 
cancer and, given that the incidence of male breast cancer 
is rising [70], this poses a challenge for modelling in a 
functional sense.
Conclusions
Tremendous advances in our understanding of the 
biology of breast cancer have been made over the past 
several decades using breast cancer cell lines. We must 
now move beyond the ‘one marker, one cell line’ studies 
of the past and use knowledge gained through genetic 
and transcriptomic proﬁ ling to use cell lines or cell line 
panels more eﬀ ectively as experimental models to study 
speciﬁ c subgroups of breast cancer, because this is likely 
to have the greatest impact on improving outcome for 
breast cancer patients.
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